Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 26;29:10732748221081369. doi: 10.1177/10732748221081369

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — PER 2 reduces the sensitivity of colorectal cancer cells to doxorubicin. (A) Changes in PER2, cleaved-PARP, and p53 protein levels in RKO cells after .2 mM Dox treatment for 0, 6, 12, and 24 h. (B) Changes in PER2, cleaved-PARP, and p53 protein levels in RKO cells treated with different concentrations of Dox (0, .1 µg/µl, .2 µg/µl, and .4 µg/µl) for 24 h. (C) Representative images of flow cytometry of PER2-knockdown and control cells treated with .2 mM Dox at different times. (D) The percentage of apoptotic cells is shown (lower panel, **** P <.0001).PER2, Period 2; Dox, doxorubicin.